VIICTR Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain. 2022 06 30; 145(6):1924-1938.
View in:
PubMed
subject areas
Adolescent
Adult
Alzheimer Disease
Amyloid beta-Peptides
Antigens, Neoplasm
Atomoxetine Hydrochloride
Biomarkers
Cell Adhesion Molecules
Cognitive Dysfunction
Cross-Over Studies
Double-Blind Method
Drug Repositioning
Humans
Inflammation
Middle Aged
Neuroprotection
Norepinephrine
tau Proteins
authors with profiles
IHAB HAJJAR